Rallybio to Present at Upcoming Investor Conferences
Rallybio (Nasdaq: RLYB), a clinical-stage biotechnology company focused on rare diseases, has announced its participation in two upcoming investor conferences. The company will be present at:
1. The 2024 Wells Fargo Healthcare Conference in Everett, MA on September 5, 2024. CEO Stephen Uden will participate in a fireside chat at 3:45 p.m. ET.
2. The H.C. Wainwright 26th Annual Global Investment Conference in New York, NY on September 10, 2024. Dr. Uden will present a corporate overview at 11:00 a.m. ET.
Live webcasts of both presentations will be available on Rallybio's website, with replays accessible for 30 days afterward.
Rallybio (Nasdaq: RLYB), un'azienda biotecnologica in fase clinica focalizzata sulle malattie rare, ha annunciato la propria partecipazione a due prossime conferenze per investitori. L'azienda sarà presente a:
1. La 2024 Wells Fargo Healthcare Conference a Everett, MA il 5 settembre 2024. Il CEO Stephen Uden parteciperà a una chiacchierata informale alle 15:45 ET.
2. La 26a Conferenza Globale Annuale sugli Investimenti H.C. Wainwright a New York, NY il 10 settembre 2024. Il Dr. Uden presenterà una panoramica aziendale alle 11:00 ET.
Le dirette streaming di entrambe le presentazioni saranno disponibili sul sito web di Rallybio, con repliche accessibili per 30 giorni successivi.
Rallybio (Nasdaq: RLYB), una empresa de biotecnología en etapa clínica centrada en enfermedades raras, ha anunciado su participación en dos próximas conferencias para inversores. La empresa estará presente en:
1. La Conferencia de Salud de Wells Fargo 2024 en Everett, MA el 5 de septiembre de 2024. El CEO Stephen Uden participará en una charla informal a las 3:45 p.m. ET.
2. La 26ª Conferencia Global Anual de Inversión H.C. Wainwright en Nueva York, NY el 10 de septiembre de 2024. El Dr. Uden presentará una visión general corporativa a las 11:00 a.m. ET.
Las transmisiones en vivo de ambas presentaciones estarán disponibles en el sitio web de Rallybio, con repeticiones accesibles durante 30 días después.
Rallybio (Nasdaq: RLYB)는 희귀 질환에 중점을 둔 임상 단계 생명공학 회사로, 두 개의 투자자 회의에 참여할 예정이라고 발표했습니다. 회사는 다음 회의에 참석합니다:
1. 2024년 9월 5일, MA 에버렛에서 열리는 2024 웰스파고 헬스케어 컨퍼런스. CEO 스티븐 우든이 오후 3시 45분 ET에 화상 대담에 참여합니다.
2. 2024년 9월 10일, NY 뉴욕에서 열리는 H.C. 웨인라이트 제26회 연례 글로벌 투자 컨퍼런스. 우든 박사가 오전 11시 ET에 기업 개요를 발표합니다.
두 프레젠테이션의 실시간 웹캐스트는 Rallybio 웹사이트에서 제공되며, 이후 30일 동안 재생이 가능합니다.
Rallybio (Nasdaq: RLYB), une société de biotechnologie en phase clinique axée sur les maladies rares, a annoncé sa participation à deux prochaines conférences pour investisseurs. La société sera présente à :
1. La Conférence sur les soins de santé de Wells Fargo 2024 à Everett, MA le 5 septembre 2024. Le PDG Stephen Uden participera à une discussion informelle à 15h45 ET.
2. La 26ème Conférence mondiale annuelle d'investissement H.C. Wainwright à New York, NY le 10 septembre 2024. Le Dr Uden présentera un aperçu de l'entreprise à 11h00 ET.
Des webdiffusions en direct des deux présentations seront disponibles sur le site Web de Rallybio, avec des rediffusions accessibles pendant 30 jours après.
Rallybio (Nasdaq: RLYB), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf seltene Krankheiten konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird an folgenden Veranstaltungen teilnehmen:
1. Auf der 2024 Wells Fargo Healthcare Conference in Everett, MA am 5. September 2024. CEO Stephen Uden wird um 15:45 Uhr ET an einem Gespräch teilnehmen.
2. Auf der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright in New York, NY am 10. September 2024. Dr. Uden wird um 11:00 Uhr ET eine Unternehmensübersicht präsentieren.
Live-Übertragungen beider Präsentationen sind auf der Website von Rallybio verfügbar, mit Zugriff auf Wiederholungen für 30 Tage danach.
- None.
- None.
-
2024 Wells Fargo Healthcare Conference in
Everett, MA on Thursday, September 5, 2024. Stephen Uden, M.D., Chief Executive Officer, will participate in a fireside chat at 3:45 p.m. ET. -
H.C. Wainwright 26th Annual Global Investment Conference in
New York, NY on Tuesday, September 10, 2024. Dr. Uden will present a corporate overview at 11:00 a.m. ET.
Live webcasts of the Wells Fargo fireside chat and H.C. Wainwright presentation will be accessible through the Events and Presentations section of Rallybio’s website at www.rallybio.com. A replay of the webcasts will be available for 30 days following each presentation.
About Rallybio
Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Rallybio is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240826376744/en/
Investors
Samantha Tracy
Rallybio Corporation
(475) 47-RALLY (Ext. 282)
investors@rallybio.com
Kevin Lui
Precision AQ
(212) 698-8691
Kevin.Lui@precisionaq.com
Media
Victoria Reynolds
Mission North
(760) 579-2134
rallybio@missionnorth.com
Source: Rallybio Corporation
FAQ
When and where is Rallybio (RLYB) presenting at the Wells Fargo Healthcare Conference in 2024?
What is the date and time of Rallybio's (RLYB) presentation at the H.C. Wainwright Global Investment Conference?
How can investors access Rallybio's (RLYB) presentations at the upcoming conferences?
What type of company is Rallybio (RLYB) and what is its focus?
